Seneca Pharmaceuticals

Seneca Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation oncolytic virus therapies for the treatment of solid tumors. The company's lead candidate, SVV-001, is a naturally occurring, non-pathogenic RNA virus that specifically targets and infects cancer cells expressing the TEM8/ANTXR1 receptor. Seneca is currently advancing SVV-001 in combination with checkpoint inhibitors to enhance anti-tumor immune responses in difficult-to-treat cancers such as neuroendocrine tumors and small cell lung cancer. By leveraging the selective tropism of the Seneca Valley Virus, the company aims to provide a potent and targeted immunotherapy option for patients with high unmet medical needs.